1 / 3

Traumatic Brain Injury (TBI) Market

Traumatic Brain Injury is defined as a penetrating head injury that disrupts the normal functioning of the brain. It may result when the head suddenly hits an object or when an object pierces the skull and enters brain tissue.

Download Presentation

Traumatic Brain Injury (TBI) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Traumatic Brain Injury is defined as a penetrating head injury that disrupts the normal functioning of the brain. It may result when the head suddenly hits an object or when an object pierces the skull and enters brain tissue. Got queries? Click here and get more insights @ Traumatic Brain Injury Market Landscape Traumatic Brain Injury Sign and Symptoms Signs and symptoms may appear directly, within 24 hours, or they'll emerge days or weeks after the injury. Sometimes the symptoms are subtle. An individual may notice a drag but not relate it to the injury. Some people will appear to possess no signs after a TBI, but their condition worsens later. Symptoms modify greatly depending on the severity of the head injury. They'll include any of the following: ●Headache ●Paralysis ●Dilated pupils ●Vision changes (blurred vision or seeing double) ●Breathing problems ●Inappropriate emotional responses ●Difficulty in speech ●Difficulty swallowing ●Body numbness ●Loss of bladder control

  2. Traumatic Brain Injury Epidemiology Insights Persons 44 years aged and younger, TBI-related deaths decreased between the periods of 2001–2002 and 2009–2010. Rates for age groups 45–64 years aged remained stable for this same ten-year period. In the last decade, rates of TBI-related deaths in men decreased from 27.8 to 25.4 per 100,000, and rates in women decreased from 9.6 to 9.0 per 100,000. Approximately 2.8 million people sustain Traumatic Brain Injury annually within the United States, and each day 153 people die from injuries that include Traumatic Brain Injury. Traumatic Brain Injury Market Insights Currently, there is no approved therapy for the treatment of Traumatic Brain Injury. The therapy is based on the injury. Mild traumatic brain injuries usually require no treatment apart from rest and over-the-counter pain relievers to treat a headache. Whereas, Emergency take care of moderate to severe traumatic brain injuries focuses on ensuring the person has enough oxygen and an adequate blood supply, maintaining blood pressure, and preventing any more extended damage to the head. Medications available are anti-seizure drugs, coma-inducing drugs, diuretics. The existing medications being used for those suffering from Traumatic Brain Injury are focused on treating the symptoms and stopping the pain instead of protecting any further damage from occurring. To overcome this shortcoming of the therapeutic market and to provide better Traumatic Brain Injury treatment options for the moderate to severe TBI patient pool, many molecules are being explored at different levels. Key pharma players involved in the development of therapies for the Traumatic Brain Injury treatment are Vasopharm GmbH, NeuroVive Pharmaceutical AB, Cellvation, and others. Request for a sample report @ Traumatic Brain Injury Market Scenario 2030 About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

More Related